Posts Tagged ‘lymphoma’


In STEM CELLS IN THE NEWS on January 4, 2013 at 9:00 am

Many years ago, researchers tested a theory of using two unrelated units of cord blood to produce an increased volume of stem cells, which would decrease the engraftment time frame in adults suffering from blood disorders. The newly expanded procedure proves promising results and will soon begin human clinical trials.

A team of researchers from the MD Anderson Cancer Center in Houston has come up with a new way to make stem cell transplants more effective in patients with leukemia, lymphoma and other blood cancers and disorders. The study, whose findings were published last week in the New England Journal of Medicine, is the first of its kind to show favorable results in manipulating one batch of stem cells in patients who undergo a double cord blood transplant. The promising results have paved the way for expanding the study from one site to an international, multicenter clinical trial.
University Hospitals Seidman Cancer Center is poised to become one of those sites. Between 15 and 25 patients will be enrolled, said Dr. Marcos de Lima, lead study author who joined UH in the fall to become section chief of hematologic malignancies and bone marrow transplantation at Seidman and professor of medicine at Case Western Reserve University School of Medicine. With study sites opening up elsewhere in the United States and in Europe, several hundred patients will be able to take part in the trial, said de Lima. He said he hopes enrollment will start within the next year.
Cord blood, which is filled with adult stem cells similar to those found in bone marrow, is extracted from an umbilical cord and placenta shortly after a baby is born. Transplanting cord blood instead of bone marrow or peripheral blood has several advantages, among them that the cord blood doesn’t have to be a perfect match for a patient. That opens up the number of potential matches that are available for patients, especially those who are ethnic minorities. But among the limitations were the time it took for donor cells to begin making new blood cells, called engraftment, and the relatively small amount of cells that can be obtained from one cord blood unit — a problem for adult patients.
The first double cord blood transplants using two unrelated units of cord blood, designed to make transplantation more effective in adults, were conducted more than a dozen years ago. The ability to produce a higher volume of stem cells from the two transplanted units still did not solve the problem of the length of time from infusion to engraftment. “The longer you go without red blood cells, white blood cells and platelets, the more trouble you have,” de Lima said. All of those things are essential to ward off infection, bleeding, and anemia.  To get around that hurdle, the MD Anderson team decided to see if they could make more of the cord blood cells in the lab in conditions that mimic that of bone marrow. One unit was transplanted unchanged, while the second unit was “expanded” in the lab — before transplant — using a type of cell found in bone marrow called mesenchymal stromal cell.
The study, which opened in 2007 and lasted for three years, enrolled 31 patients at MD Anderson, all of whom received two cord blood units with the new treatment. An additional 140 patients from MD Anderson and elsewhere also received two units of unmanipulated cord blood, and were the control group. The result of the expansion treatment was quicker engraftment, compared to other patients treated with the more traditional double cord blood transplant method. The most unexpected study outcome, de Lima said, was the reduction in time it took to resume production of platelets, a key in protecting against excessive bleeding.
“Traditionally, platelets are a big problem,” said de Lima, adding that patients typically have to undergo numerous transfusions. With the new method, “We saw much more consistent, solid [development], and people needed less transfusion. That was a pleasant surprise,” he said.



GENE WILDER: SECRET OF LIFE – Celebrity News | Gossip – National Enquirer

In CELEBRITIES & STEM CELLS on May 18, 2010 at 4:15 am

Gene battled non-Hodgkin’s lymphoma in 1999.  He went through chemotherapy and a stem cell transplant, and in 2002 doctors confirmed his cancer was in remission.


Photo by: Walter Mirisch Corp. “Willy Wonka”

Willy Wonka star GENE WILDER — on beyond Oompa Loompas.

The legendary comic actor says he’s found the secret to extending his life — his two new dogs!

At a reading of his new collection of short stories – What Is This Thing Called Love? – at a New York City bookstore , the cancer survivor, 76, gushed about brand-new pooches Maltese and Maltipoo.

“When we got them, I figured they would either shorten my life or lengthen my life,” he quipped, sitting on stage with fourth wife, Karen Webb.

“I wasn’t really sure which it would be. But now I think they are lengthening it, because we play together and we have a lot of fun together.”

Gene – famous for his roles in Blazing Saddles, Willy Wonka & the Chocolate Factory, The Frisco Kid and Young Frankenstein – battled non-Hodgkin’s lymphoma in 1999.

He went through chemotherapy and a stem cell transplant, and in 2002 doctors confirmed his cancer was in remission.

Although Gene appeared frail-looking, he and wife Karen seemed happy together.

Gene and Karen, 59, met in 1988 when Karen worked as a speech pathologist and Gene was researching his role as a deaf man for See No Evil, Hear No Evil with Richard Pryor.

He reconnected with her after third wife Gilda Radner’s death from ovarian cancer in 1989, and the two married in 1991.

“I know what love is now, and I’ve found it,” said Gene. “She’s sitting right next to me.”

via GENE WILDER: SECRET OF LIFE – Celebrity News | Gossip – National Enquirer.


In ALL ARTICLES, VICTORIES & SUCCESS STORIES on December 9, 2009 at 10:15 pm
Hodgkin's lymphoma cells. This form of cancer begins in a lymph node—often in the neck—then progresses to other nodes. (Photograph by Andrejs Liepins. Reproduced by permission of Photo Researchers, Inc.)

Hodgkin's lymphoma cancer cells begin in a lymph node—often in the neck—then progress to other nodes.






In 2003, 13 year-old Kirk Lee was diagnosed with Hodgkins Lymphoma, a disease that affects the body’s lymph nodes.

Kirk Lee first noticed something was wrong when he detected a knot on his neck. His grandmother Carolyn Lee said he was taken to the hospital and consequently diagnosed with Hodgkins Lymphoma. He was immediately transported to Jackson for surgery to remove tissue from his lungs and undergo chemotherapy.

After receiving radiation, chemotherapy and some experimental treatment in Jackson, Lee still had third-stage lymphoma, meaning the disease was in his abdomen and his neck. (1)

When neither of those treatments was successful, he was taken for stem cell transplant therapy.

That stem cell treatment put his illness into remission.

*     * *     *     *

To see if you are a candidate for stem cell treatment for Hodgkin’s Lymphoma, click here [ REQUEST INFO ]

Hodgkin's Disease (After Chemotherapy)

via story

Ethan Zohn looks to survive Hodgkin’s Lymphoma (+chemo)

In CELEBRITIES & STEM CELLS on October 8, 2009 at 4:08 pm

Ethan Zohn

Three months of chemotherapy this past summer weren’t enough to knock out Ethan Zohn’s case of Hodgkin’s lymphoma. So he’s back in the hospital, connected to tubes and wires, undergoing even more chemotherapy – and in his latest video diary, he takes viewers inside his tiny room to share the experience and let his fans know how he’s doing.

“I have been locked in this room for three days, and I’ve gone a little bit stir crazy, I’m not gonna lie,” says the Survivor: Africa winner, reclining in a hospital bed in part one of a new three-stage battle he’s waging against the resurgent cancer.


Ethan Zohn_ & Jenna Morasca

In late August, Zohn discovered that the cancer he had been treating since May had actually spread. Last month, he began an intense treatment regimen, starting with two new chemo sessions. Those will be followed by radiation therapy, and – in December – a complete stem-cell replacement therapy that will keep him in the hospital for 30 days straight.

Finding a way to break his stir-craziness after three days, the always-driven athlete says in the video that he was excited to finally get up and walk around – just before taping his message to viewers.


Ethan Zohn - Survivor

“They finally let me out in the hallway where I could do some walking,” he says. “Fourteen laps [around the hall] is a mile, and of course I tried to break the record – so I did 28 laps. Which I’m pretty happy about.”

Showing his usual upbeat nature, Zohn adds that he’s feeling positive about the new chemotherapy: “So far so good. I feel it killing all the cancer in my body, and I’m excited to keep doing what I’m doing – and I’ll see you soon,” he says.

via {alltv} Getting Chemo with Ethan Zohn | Hottest Celebrity Photos 2009.


In VICTORIES & SUCCESS STORIES on October 6, 2009 at 12:40 pm

Ga. bone marrow donor meets recipient in Ill.

Bone marrow aspiration

Bone marrow aspiration

1:47 p.m. CDT, October 5, 2009

MAYWOOD, Ill. – It was an emotional moment when Illinois cancer survivor Rosalind Beard met the Georgia man who donated his bone marrow to help her fight Hodgkin’s lymphoma.

Beard, a 37-year-old mother of four from Melrose Park, and Tim Crawford, 40, of Adairsville, Ga., cried and embraced Sunday when they met for the first time at Loyola University Medical Center in Maywood, a Chicago suburb.

The pair had to wait two years to meet because of confidentiality agreements, but Beard said it was important to thank Crawford personally.

“He saved me,” she said. “We have the same stem cells, so I feel like I knew him already.”…


Hodgkin's lymphoma cells

via Ga. bone marrow donor meets recipient in Ill. — chicagotribune.com.

SGEN Seattle Genetics Finalizes Enrollment of Its Brentuximab Vedotin (SGN-35) Pivotal Trial

In BUSINESS OF STEM CELLS on August 26, 2009 at 3:47 am

Aug 25, 2009 (Close-Up Media via COMTEX) — SGEN | Quote | Chart | News | PowerRating — Seattle Genetics, Inc. announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma.

Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company's proprietary ADC technology.

“Strong interest in brentuximab vedotin from investigators and patients has allowed us to rapidly complete our target enrollment of 100 patients in the pivotal trial in six months, emphasizing the substantial unmet medical need in the relapsed and refractory Hodgkin lymphoma setting,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “The pivotal trial allows for patient treatment up to approximately one year, and we expect data to be available in the second half of 2010. Our goal is to submit both a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under the accelerated approval regulations and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA) for conditional marketing authorization in the first half of 2011. Assuming priority review of our NDA, we would then plan to commercially launch the drug in the United States in the second half of 2011, with potential European launch to follow.”

via SGEN Seattle Genetics Finalizes Enrollment of Its Brentuximab Vedotin (SGN-35) Pivotal Trial.

%d bloggers like this: